A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-04 | actual | When the study began enrolling |
| Primary completion | 2026-05-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft Versus Host Disease
Intervention
- Drug: Belumosudil — also filed as SAR445761/ KD025, Rezurock
Primary outcome
what the primary-completion date above is the date OFPlasma concentrations of belumosudil at specified time points
measured At Day 1 and Day 29(±3)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed